Akorn acquires NDA and all privileges to Betimol from Santen Akorn.

Akorn acquires NDA and all privileges to Betimol from Santen Akorn, Inc.25 percent & 0.5 percent from Santen. This acquisition enhances our platform and growth opportunities in 2014 further. Financial Influence of the Transaction This transaction is likely to add around $8 million to $9 million in revenues to 2014 and approximately $0.03 to $0.04 of adjusted net income per diluted share.On the basis of the findings of the GeparDuo study ,16 we assumed that the rate of pathological complete response with epirubicin and cyclophosphamide accompanied by docetaxel would be 14 percent; we expected that the price of pathological total response with epirubicin and cyclophosphamide accompanied by docetaxel plus bevacizumab would be 18.9 percent . With these assumptions, we approximated that we would need to enroll 1876 sufferers, regarding to a two-sided continuity-corrected Pearson’s chi-square test with an alpha degree of 0.05 and a beta degree of 0.20.